Wednesday, July 8, 2026

Drug profile · INN

repository corticotropin

repository corticotropin (H.P. ACTHAR GEL) is a melanocortin receptor 2 agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — repository corticotropin
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

repository corticotropin (H.P. ACTHAR GEL) is a melanocortin receptor 2 agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN repository corticotropin
Brand H.P. ACTHAR GEL
Mechanism Melanocortin receptor 2 agonist
Target Adrenocorticotropic hormone receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Melanocortin receptor 2 agonist

Primary target: Adrenocorticotropic hormone receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. cosyntropin Melanocortin receptor 2 agonist
  2. corticotropin Melanocortin receptor 2 agonist
  3. corticotropin-zinc hydroxide Melanocortin receptor 2 agonist
  4. tetracosactide Melanocortin receptor 2 agonist

Frequently asked questions

What is repository corticotropin?

repository corticotropin (H.P. ACTHAR GEL) is a melanocortin receptor 2 agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for repository corticotropin?

H.P. ACTHAR GEL is a marketed brand name for repository corticotropin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of repository corticotropin?

repository corticotropin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.